In the evolving landscape of medical device regulation, regulatory bodies like the FDA are increasingly recognizing the value of Real-World Evidence (RWE) in supporting decision-making. While traditional clinical trials remain essential, Real-World Data (RWD) provides critical insights into how devices perform in real clinical settings.
This article provides a structured framework to understand:
- The difference between RWD and RWE
- How RWE compares with clinical trials
- Where RWE fits in FDA regulatory pathways (PMA, De Novo, post-market)
- Key requirements for data reliability and relevance
- Practical advantages and limitations